Home Cart Sign in  
Chemical Structure| 923604-59-5 Chemical Structure| 923604-59-5

Structure of Simeprevir
CAS No.: 923604-59-5

Chemical Structure| 923604-59-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Simeprevir (TMC435; TMC435350) is an oral, potent, and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a Ki of 0.36 nM. It inhibits HCV replication with an EC50 of 7.8 nM and also potently suppresses SARS-CoV-2 replication, synergizing with Remdesivir. Simeprevir inhibits the main protease (Mpro) and RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2 and modulates host immune responses.

Synonyms: TMC435350; TMC435

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Simeprevir

CAS No. :923604-59-5
Formula : C38H47N5O7S2
M.W : 749.94
SMILES Code : C(NS(=O)(=O)C1CC1)(=O)[C@]23[C@@](C2)(/C=C\CCCCN(C)C(=O)[C@]4([C@](C(=O)N3)(C[C@@H](OC=5C6=C(N=C(C5)C7=NC(C(C)C)=CS7)C(C)=C(OC)C=C6)C4)[H])[H])[H]
Synonyms :
TMC435350; TMC435
MDL No. :MFCD25563225

Safety of Simeprevir

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
MDCK cells 200 nM 72 hours Simeprevir significantly mislocalized both LactC2 and KRASG12V from the plasma membrane PMC8713765
Huh7 cells 11 nM 48 hours Evaluate the inhibitory effect of Simeprevir on HCV genotype 1a and 1b replicons, results showed EC50 values of 7 nM and 4 nM for 1a and 1b replicons, respectively PMC5192143
Vero E6 cells 0–10 μM 24 hours To evaluate the antiviral effects of simeprevir on SARS-CoV-2 replication, results showed that simeprevir could inhibit SARS-CoV-2 replication in Vero E6 cells with an EC50 of 1.41 ±0.12 μM PMC8679493
HEK293 cells 10 nM 60 minutes Induced apoptosis PMC10682029
HCT116 cells 10 nM 60 minutes Induced apoptosis PMC10682029
HT29 cells 10 nM 90 minutes Induced apoptosis PMC10682029

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
mice pancreatic cancer xenograft model subcutaneous injection 100 μg/mouse single dose, serum collected 6 hours after dosing Simeprevir showed a dose-dependent response in inhibiting tumor growth, with a ~28% reduction in tumor size at 3 mg/kg, while 10 mg/kg proved to be too toxic PMC8713765
transgenic hACE2 mice SARS-CoV-2 infection model intraperitoneal injection 0.04, 0.2, 1, 5, 25 mg/kg Once daily for 3 to 16 days To assess the in vivo antiviral efficacy of simeprevir, results showed that simeprevir failed to suppress SARS-CoV-2 replication PMC8679493
SCID mice HT29 xenograft model Oral 100 μg/mouse single dose, serum collected 6 hours after dosing Induced complete tumor regression PMC10682029

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00752544 HCV PHASE1 COMPLETED 2025-11-08 -
NCT00866853 Hepatitis C|Viruses PHASE1 COMPLETED 2025-07-09 -
NCT01567735 Hepatitis C PHASE3 COMPLETED 2014-03-20 Antwerpen, Belgium|Brussel, Be... More >>lgium|Edegem, Belgium|Clichy, France|Creteil, France|Lyon, France|Paris, France|Villejuif Cedex, France Less <<
NCT01046058 Hepatitis C Virus PHASE1 COMPLETED 2025-07-11 Anaheim, California, United St... More >>ates|Orlando, Florida, United States|San Antonio, Texas, United States Less <<
NCT01022125 Hepatitis C Virus PHASE1 COMPLETED 2025-04-10 -
NCT01381835 Hepatitis C Virus PHASE1 COMPLETED 2025-01-12 Prague 7, Czech Republic
NCT01799603 Healthy PHASE1 COMPLETED 2025-07-12 Toshima, Japan
NCT00752648 Hepatitis C|HCV PHASE1 COMPLETED 2025-01-09 -
NCT01323244 Hepatitis C PHASE3 COMPLETED 2025-03-15 Bakersfield, California, Unite... More >>d States|Los Angeles, California, United States|San Diego, California, United States|Englewood, Colorado, United States|Jacksonville, Florida, United States|Orlando, Florida, United States|New Orleans, Louisiana, United States|Jackson, Mississippi, United States|Tupelo, Mississippi, United States|Chapel Hill, North Carolina, United States|Cincinnati, Ohio, United States|Philadelphia, Pennsylvania, United States|Dallas, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Buenos Aires, Argentina|Rosario, Santa Fe, Argentina|Adelaide, Australia|Concord, Australia|Melbourne, Australia|Wentworthville, Australia|Woolloongabba N/A, Australia|Wien, Austria|Antwerpen, Belgium|Brussels, Belgium|Gent, Belgium|Sao Paulo, Brazil|Sofia, Bulgaria|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Grenoble, France|Lyon, France|Nice Cedex 03 N/A, France|Paris Cedex 12, France|Berlin, Germany|Frankfurt A. M., Germany|Hamburg, Germany|Kiel, Germany|Münster, Germany|Ulm, Germany|Würzburg, Germany|Haifa, Israel|Zefat, Israel|Monterrey, Mexico|Amsterdam, Netherlands|Rotterdam, Netherlands|Auckland, New Zealand|Christchurch, New Zealand|Bydgoszcz, Poland|Chorzów, Poland|Czeladz, Poland|Kielce, Poland|Myslowice, Poland|Warschau, Poland|Coimbra, Portugal|Lisboa, Portugal|San Juan, Puerto Rico|Bucuresti, Romania|Moscow, Russian Federation|Saint-Petersburg, Russian Federation|Samara, Russian Federation|Smolensk, Russian Federation|St Petersburg, Russian Federation|Stavropol, Russian Federation|Barcelona, Spain|Madrid, Spain|Sevilla N/A, Spain|Valencia, Spain|Donetsk, Ukraine|Kyiv, Ukraine|Vinnitsa, Ukraine|Birmingham, United Kingdom|London, United Kingdom Less <<
NCT00812331 Hepatitis C PHASE2 COMPLETED 2025-11-09 Brugge, Belgium|Brussels, Belg... More >>ium|Bruxelles, Belgium|Gent, Belgium|Leuven, Belgium|Berlin, Germany|Frankfurt N/A, Germany|Freiburg, Germany|Hannover, Germany|Bangkok, Thailand|Chiang Mai, Thailand Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.33mL

0.27mL

0.13mL

6.67mL

1.33mL

0.67mL

13.33mL

2.67mL

1.33mL

References

 

Historical Records

Categories